DESCRIPTION OF THE SURVEY
Patients infected with or cured of hepatitis C are invited to participate in a survey concerning the psychological effects of hepatitis C.
WHAT WILL MY PARTICIPATION INVOLVE?
If you decide to participate in this survey, you will be asked to answer several questions. Based on your answers, your questions may vary. You will be asked to complete one survey. Your participation will last approximately 15-20 min.
HOW WILL MY CONFIDENTIALITY BE PROTECTED?
This study is anonymous. Neither your name nor any other identifiable information will be recorded. This survey is HIPAA-enabled allowing to help keep your protected health information safe.
Click the link to access the survey here: https://www.surveymonkey.com/r/HCMSGSurvey
By Linda A. Johnson, AP Business Writer |
A federal jury in California has ruled in favor of drugmaker Merck & Co. in a high-stakes lawsuit against rival Gilead Sciences Inc. over patents for lucrative new drugs that rapidly cure hepatitis C.
Merck accused Gilead of infringing on patents it filed over a decade ago, claiming Gilead’s sofosbuvir infringes on those patents. Merck, which is based in Kenilworth, New Jersey, is seeking billions in damages and royalties on sales of Gilead’s two hepatitis drugs.
Sofosbuvir is the active ingredient in Gilead’s Sovaldi and a component of its Harvoni. They were launched in 2013 and 2014, respectively, and became blockbusters overnight. Together, the two drugs brought in $19.1 billion last year — nearly two-thirds of total revenue for Gilead, a biologic drugmaker based in Foster City, California.
By Cara DeGette
Editor’s update: A transparency bill targeting runaway drug prices that had widespread and bipartisan support in both chambers of the Colorado Legislature — and the support of the Eagle County commissioners — was killed 9-4 by the House Committee on Health, Insurance and Environment on Thursday.
The bill was one of 11 such measures around the country drafted in response to the skyrocketing costs of pharmaceuticals. Veteran healthcare reporter Cara DeGette wrote about those out-of-control drug prices for RealVail.com partner Rocky Mountain Post on Thursday, and RMP also delved into the topic last month.
Here’s what the liberal-leaning lobby group the Colorado Center on Law and Policy wrote Friday about Thursday’s legislative action on drug prices:
“HB 1102, which would have required prescription drug manufacturers to provide data on cost components of expensive drugs, with a report going back to the state legislature, was killed by the House Committee on Health, Insurance and Environment on Thursday.
More than 2.3 million people internationally are infected with both HIV and hepatitis C, according to estimates from a study released Tuesday at the University of Bristol and the London School of Hygiene & Tropical Medicine.
The study, which was the first to look at the simultaneous infection of HIV and hepatitis C, was published in the online journal “The Lancet Infectious Diseases” and sponsored by the World Health Organization.